I thought there was a call scheduled tonight? Did I misinterpret some of the earlier posts?
Fantasy Football - Footballguys Forums
This is a sample guest message. Register a free account today to become a member! Once signed in, you'll be able to participate on this site by adding your own topics and posts, as well as connect with other members through your own private inbox!
***OFFICIAL CYDY/Leronlimab Thread*** (5 Viewers)
- Thread starter This_Guy
- Start date
⚡DEADHEAD⚡
Footballguy
I'm not sure I ever saw anything confirmatory about a call.
ChiefD
Footballguy
adonis
Footballguy
Never saw info about a call. My understanding of results would be that they were unlikely to be released today, but if anything was happening, they'd be going to the FDA first and then could release news.
But honestly, at this point anything could be happening.
Sand
Footballguy
Sand
Footballguy
⚡DEADHEAD⚡
Footballguy
So I've been curious to learn what other company paths to NASDAQ from OTC look like. Here's an example. We should be careful about expecting to see uplisting news 6 weeks to the day after the application was filed.
On February 13, 2019, a company called Dyadic International, a biotech firm, announced a desire to move up from the OTCQX to NASDAQ. Here's some info shared in the PR that day.
JUPITER, FL / ACCESSWIRE / February 13, 2019 / Dyadic International, Inc. (the "Company") (OTCQX: DYAI) today announced that the Securities and Exchange Commission (the "SEC") has declared the Company's Registration Statement on Form 10-12G (the "Form 10") effective as of February 12, 2019. As a result, the Company is now subject to the periodic and current reporting requirements of Section 13(a) of the Securities and Exchange Act of 1934.
A copy of Dyadic's Form 10 is available at www.sec.gov under the name of Dyadic International or in the Investor Relations section of Dyadic's website at www.dyadic.com.
In addition, the Company announced that it has filed an application to list its common stock on The NASDAQ Capital Markets Exchange ("NASDAQ").
"We are pleased to announce these milestones and are working to satisfy the NASDAQ listing requirements, including the requirement for our shares to have a minimum closing price of $2 per share for 90 consecutive trading days or $3 per share for five consecutive trading days," said Mark Emalfarb, Chief Executive Officer of Dyadic. He further stated that "we believe that our strong cash position, along with continued progress from our science and business development activities and our new status as an SEC reporting company will lead to long term value for our shareholders."
On April 15, Dyadic announced NASDAQ approved it for uplisting.
JUPITER, FL / ACCESSWIRE / April 15, 2019 / Dyadic International, Inc. ("Dyadic") (OTCQX: DYAI), a global biotechnology company focused on further improving and applying its proprietary C1 gene expression platform to speed up the development, lower production costs and improve the performance of biologic vaccines and drugs at flexible commercial scales, is pleased to announce that its common stock has been approved to list on The Nasdaq Capital Market.
Trading on the Nasdaq is expected to commence on or about April 17, 2019 under the trading symbol DYAI. Currently, Dyadic's stock is listed on the OTCQX market, which is operated by the OTC (Over-the-Counter) Markets Group.
"Our listing on the Nasdaq is a major milestone for the company and a true indicator of our growth. We believe that listing on the Nasdaq will enhance our visibility in the marketplace, increase the liquidity of our stock, broaden our shareholder base by attracting new investors and ultimately, build long-term shareholder value," said Mark Emalfarb, Dyadic's Chief Executive Officer.
On February 13, 2019, a company called Dyadic International, a biotech firm, announced a desire to move up from the OTCQX to NASDAQ. Here's some info shared in the PR that day.
JUPITER, FL / ACCESSWIRE / February 13, 2019 / Dyadic International, Inc. (the "Company") (OTCQX: DYAI) today announced that the Securities and Exchange Commission (the "SEC") has declared the Company's Registration Statement on Form 10-12G (the "Form 10") effective as of February 12, 2019. As a result, the Company is now subject to the periodic and current reporting requirements of Section 13(a) of the Securities and Exchange Act of 1934.
A copy of Dyadic's Form 10 is available at www.sec.gov under the name of Dyadic International or in the Investor Relations section of Dyadic's website at www.dyadic.com.
In addition, the Company announced that it has filed an application to list its common stock on The NASDAQ Capital Markets Exchange ("NASDAQ").
"We are pleased to announce these milestones and are working to satisfy the NASDAQ listing requirements, including the requirement for our shares to have a minimum closing price of $2 per share for 90 consecutive trading days or $3 per share for five consecutive trading days," said Mark Emalfarb, Chief Executive Officer of Dyadic. He further stated that "we believe that our strong cash position, along with continued progress from our science and business development activities and our new status as an SEC reporting company will lead to long term value for our shareholders."
On April 15, Dyadic announced NASDAQ approved it for uplisting.
JUPITER, FL / ACCESSWIRE / April 15, 2019 / Dyadic International, Inc. ("Dyadic") (OTCQX: DYAI), a global biotechnology company focused on further improving and applying its proprietary C1 gene expression platform to speed up the development, lower production costs and improve the performance of biologic vaccines and drugs at flexible commercial scales, is pleased to announce that its common stock has been approved to list on The Nasdaq Capital Market.
Trading on the Nasdaq is expected to commence on or about April 17, 2019 under the trading symbol DYAI. Currently, Dyadic's stock is listed on the OTCQX market, which is operated by the OTC (Over-the-Counter) Markets Group.
"Our listing on the Nasdaq is a major milestone for the company and a true indicator of our growth. We believe that listing on the Nasdaq will enhance our visibility in the marketplace, increase the liquidity of our stock, broaden our shareholder base by attracting new investors and ultimately, build long-term shareholder value," said Mark Emalfarb, Dyadic's Chief Executive Officer.
⚡DEADHEAD⚡
Footballguy
I'm also finding CYDY's use of proactiveinvestors is not all that unusual for companies seeking to get to the next level (NASDAQ). That seems to be part of a playbook. So maybe somebody is advising NP on the path (not that I'm endorsing the clown show we've seen thus far).
Charlie Harper
Footballguy
Don't think there was ever a call today, CYDY was supposed to meet with the FDA today for interim analysis on S/C with a decision "in a week". Whether that's an actual week or a NP week, I don't know. It seems like the ball is in the FDA court right now.....if there was actually a meeting today.
I get the shorts. Too many IFs in regards timelines with NP.
I get the shorts. Too many IFs in regards timelines with NP.
I can live with no news for a while if it means I can churn 1000 shares everyday for an easy $200 gain. At this rate, my million dollar number is still five bucks per share, but it'll take me 5000 trading days to get there. What's that 20 years? Impeccable timing for retirement.
⚡DEADHEAD⚡
Footballguy
FreeBaGeL
Footballguy
FWIW
$1.98 when they filed.
$3.22 when they uplisted.
$7.31 two months later.
$9.08 today.
Last edited by a moderator:
Jayrok
Footballguy
Clinical Trials and Research Weekly Roundup - Safety & Efficacy of Leronlimab for COVID-19
Talk about the trial at Baylor Medical Center starting around 1:10.
Talk about the trial at Baylor Medical Center starting around 1:10.
Dwayne Hoover
Footballguy
I honestly think its more the nature of the stock. It's an unlisted startup. It being OTC makes it really hard to get mentions by bigger news sources. CNBC will not talk about an OTC stock just to name one. If you can't get PR the organic way by having outside sources cover you, you resort to whatever tactic you can to put yourself out there.
⚡DEADHEAD⚡
Footballguy
If this is true - and I think you're on target here - the NASDAQ uplisting is critical, maybe existential.
Otis
Footballguy
EVERY week is a big week. EVERY day there’s a big call and something bigbigbigigbghuuuuge is gonna happen.
needanap
Footballguy
Shorts will have a field day with NP selling at $4.97. He was granted 323,000 shares for $0 and sold half at $4.97. This happened 7/31.
SEC Filing
Seems like code "F" indicates that 1/2 were sold to pay taxes on the entire grant. Makes sense, but sure it will get twisted.
SEC Filing
Seems like code "F" indicates that 1/2 were sold to pay taxes on the entire grant. Makes sense, but sure it will get twisted.
Last edited by a moderator:
Charlie Harper
Footballguy
needanap
Footballguy
I just did a quick search on code F sale, someone else may no better. What I took it to mean is he was gifted 350,000 shares which created a tax liability of $X. He sold half of the gifted shares to pay the $X tax liability. So now he has another 175,000 shares at a price of $4.97. Seems somewhat bullish that he kept at this price, I assume he could have sold them all.
djmich
Footballguy
⚡DEADHEAD⚡
Footballguy
I guess there's never a good time to sell. And there probably isn't a good time to do so for CYDY in the next 6 months, optics-wise.
Yep. Stock grants are taxed as income, not capital gains. You can either pay cash or sell some. Seeing as how that was $1.5M worth, he’s getting hit for the highest tax bracket and state income taxes.
While he still has to do his taxes but basically he doesn’t have to pay any more taxes on the $1.5M. If it goes to $10, then he pays capital gains (short or long) on the extra $5.03 per share on the shares he has left.
Taxguy
Footballguy
Correct. Depends on the type of option, stock award, etc but this sell to cover is pretty common. He picks up ordinary income at fmv * number of shares and then sells a portion to cover the tax bill on all the shares. After this he would have short/long term capital gains/losses from here but his cost basis would be $4.97 on his remaining shares from this lot.
Unfortunately, you are correct that this will be a short hit piece like clockwork. Unless he had $750k in cash on hand, there’s nothing he could have done. Once they vest (could be immediate like his or over several years), you have to pay the taxes right then and there with either cash or selling shares.
Most people don’t know how this works so they will read a hit piece and think OMG NP is selling, he doesn’t believe. Anyone who understands it sees a normal transaction.
Chaz McNulty
Footballguy
Totally. He owns 2.3M total shares now. If he really suspected that LL had no chance of treating Covid, he would sell a lot more than 175K. We all know that the stock will go back down to $1-2 if it strikes out on Covid.
Charlie Harper
Footballguy
Man I hope we have the right read. If I didn't have this thread I can see how AF can steer people away.
djmich
Footballguy
It’s a CYDY thing.
On the positive side they are hopefully looking to get Nader some shares while the price is at $5 instead of $10
Jayrok
Footballguy
krista4
Footballguy
I'm probably going to be sorry I blackdotted this, but I've been following anyway. I am not an investor, but this is just the way it's done all the freaking time. There is nothing even a dumdum short-guy should make of this.
krista4
Footballguy
Bob Sacamano
Footballguy
I've been thinking about this for a while, and I've come to the conclusion that that's a lot of effing SAEs for a placebo. Isn't this basically just simple syrup? What the actual hell?
I used to think I'd never participate in one of these because of the dangers of a new drug, but now I'm afraid of getting a placebo. Is that normal in these things?
I used to think I'd never participate in one of these because of the dangers of a new drug, but now I'm afraid of getting a placebo. Is that normal in these things?
Nick Vermeil
Footballguy
Dum-dum short guys make a living publishing false information. He he's going to maximize his gains he absolutely has to (much less should) use this information to drive the price down.
Bluto Blutarsky
Footballguy
Ducking love learning this stuff. I’m here because of the science this potentially has, but am pretty new to stocks. Not just you but others also have been a great follow through this.
Thank you
krista4
Footballguy
krista4
Footballguy
Charlie Harper
Footballguy
The SAEs on the placebo arm show the impact of COVID because like you said placebo is just sugar. Basically they weren't being treated with anything.
So having LL decrease SAEs is a good information for us.
Last edited by a moderator:
djmich
Footballguy
Good, last thing we need is another Otis, fantasycurse, don hutson, jumping off the bridge every time Adam Fuerstein farts.
Jayrok
Footballguy
Welcome! Oh he is absolutely going to make an article of this. It's what he does, and it usually results in holders, who don't know or understand what's going on, to sell. "CEO sells! He must know the data is awful!!111"
I don't think an insider is allowed to sell shares based on inside news or he'll have bigger problems. And if he was selling like that, why just that amount?
It is normal and they've done it in the recent past and it's always been a logical explanation. But it doesn't matter, the shortikine storm will happen in the morning. Should make for a decent buying day. There is a slim chance that CYDY investors are hip to the short attacks that always (read: ALWAYS) follow these filings and maybe they won't fall for it and sell this time. Plus, there shouldn't be a lot of stop loss triggers at this price. Not like there were at $10.
krista4
Footballguy
I'm not an investor just because I'm not an OTC person - too risk-averse, and would be going crazy like some of those guys. But I'm definitely hoping for the best for all of you, and ideally I'll be very sorry I wasn't in on this.Huh? There’s literally two things that could happen when you are granted stock. Sell shares to pay for taxes or pull $700k out of your pocket and pay the taxes with cash on hand. If you don’t have that much cash then you have to sell to cover. Getting a stock grant that vests immediately (if vesting over years no taxes until vested) is like getting a bonus. Your bonus gets whacked as it will be at your highest tax bracket. $1.5M is the top bracket.
There is no timing. See to cover taxes and that’s it. Nothing else to be done.
krista4
Footballguy
Great post, but the only issue is this. Because he settled his purchase with shares going back to the company, there's no insider trading aspect. The company and the "insider" would be deemed to have the same "inside information."
